Vor Biopharma Inc - Asset Resilience Ratio
Vor Biopharma Inc (VOR) has an Asset Resilience Ratio of 63.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VOR PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Vor Biopharma Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Vor Biopharma Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Vor Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Vor Biopharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $321.65 Million | 63.47% |
| Total Liquid Assets | $321.65 Million | 63.47% |
Asset Resilience Insights
- Very High Liquidity: Vor Biopharma Inc maintains exceptional liquid asset reserves at 63.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vor Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare Vor Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Vor Biopharma Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Vor Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.65% | $58.72 Million | $464.13 Million | +5.67pp |
| 2024-12-31 | 6.98% | $9.98 Million | $142.89 Million | -43.45pp |
| 2023-12-31 | 50.43% | $105.81 Million | $209.83 Million | -7.21pp |
| 2022-12-31 | 57.63% | $172.54 Million | $299.37 Million | +21.50pp |
| 2021-12-31 | 36.14% | $87.67 Million | $242.59 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $75.91 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more